PuSH - Publikationsserver des Helmholtz Zentrums München

Hartleben, G. ; Schorpp, K.K. ; Kwon, Y. ; Betz, B. ; Tsokanos, F.-F. ; Dantes, Z.* ; Schäfer, A.* ; Rothenaigner, I. ; Monroy Kuhn, J.M. ; Morigny, P. ; Mehr, L. ; Lin, S. ; Seitz, S. ; Tokarz, J. ; Artati, A. ; Adamski, J. ; Plettenburg, O. ; Lutter, D. ; Irmler, M. ; Beckers, J. ; Reichert, M.* ; Hadian, K. ; Zeigerer, A. ; Herzig, S. ; Berriel Diaz, M.

Combination therapies induce cancer cell death through the integrated stress response and disturbed pyrimidine metabolism.

EMBO Mol. Med.:e12461 (2021)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
By accentuating drug efficacy and impeding resistance mechanisms, combinatorial, multi-agent therapies have emerged as key approaches in the treatment of complex diseases, most notably cancer. Using high-throughput drug screens, we uncovered distinct metabolic vulnerabilities and thereby identified drug combinations synergistically causing a starvation-like lethal catabolic response in tumor cells from different cancer entities. Domperidone, a dopamine receptor antagonist, as well as several tricyclic antidepressants (TCAs), including imipramine, induced cancer cell death in combination with the mitochondrial uncoupler niclosamide ethanolamine (NEN) through activation of the integrated stress response pathway and the catabolic CLEAR network. Using transcriptome and metabolome analyses, we characterized a combinatorial response, mainly driven by the transcription factors CHOP and TFE3, which resulted in cell death through enhanced pyrimidine catabolism as well as reduced pyrimidine synthesis. Remarkably, the drug combinations sensitized human organoid cultures to the standard-of-care chemotherapy paclitaxel. Thus, our combinatorial approach could be clinically implemented into established treatment regimen, which would be further facilitated by the advantages of drug repurposing.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Cancer Metabolism ; Integrated Stress Response ; Metabolic Vulnerabilities ; Pyrimidine Metabolism ; Tricyclic Antidepressants
ISSN (print) / ISBN 1757-4676
e-ISSN 1757-4684
Zeitschrift EMBO Molecular Medicine
Quellenangaben Band: , Heft: , Seiten: , Artikelnummer: e12461 Supplement: ,
Verlag Wiley
Verlagsort Chichester
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Cancer (IDC)
Institute of Molecular Toxicology and Pharmacology (TOXI)
Institute of Diabetes and Obesity (IDO)
Molekulare Endokrinologie und Metabolismus (MEM)
Institute of Medicinal Chemistry (IMC)
Institute of Experimental Genetics (IEG)
CF Metabolomics & Proteomics (CF-MPC)
Förderungen Helmholtz Alliance "Aging and Metabolic Programming, AMPro"
German Research Foundation